Cetin, B. Et Al. 2021. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2 , 408-413.

Cetin, B., Gonul, I. I., Gumusay, Ö., AFŞAR, B., Bilgetekin, I., ÖZET, A., ... ÜNER, A.(2021). Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, 408-413.

Cetin, Bulent Et Al. "Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib," JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, 408-413, 2021

Cetin, Bulent Et Al. "Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, pp.408-413, 2021

Cetin, B. Et Al. (2021) . "Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, pp.408-413.

@article{article, author={Bulent Cetin Et Al. }, title={Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib}, journal={JOURNAL OF CANCER RESEARCH AND THERAPEUTICS}, year=2021, pages={408-413} }